Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

Inhibitex, Inc. today announced that its collaborator, Pfizer, Inc., has initiated patient recruitment for 408-patient, randomized, double-blind Phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus (S. aureus) vaccine (SA3Ag) in healthy adults.

12 Jan 2010

ViroPharma signs agreement with Sanquin Blood Supply Foundation to develop and commercialize Cinryze

ViroPharma Incorporated today announced that it has signed an agreement with Sanquin Blood Supply Foundation for rights to develop, file regulatory dossiers, and commercialize Cinryze(TM) (C1 esterase inhibitor [human]) for hereditary angioedema (HAE) as well as for potential new indications in certain European and rest of world (ROW) territories.

12 Jan 2010

Sorrento Therapeutics, Scripps Research Institute announce antibody development collaboration

Sorrento Therapeutics, Inc. today announced an antibody discovery and development collaboration with The Scripps Research Institute, La Jolla, CA. Under the terms of the agreement, Sorrento Therapeutics obtains an exclusive, worldwide license to the Institute's novel technology, based on quorum sensing, for the prevention and treatment of Staphylococcus aureus ('Staph') infections, including Methicillin-resistant Staph. aureus (MRSA).

12 Jan 2010

LSUHSC receives $2.1 million grant for pneumonia research

Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to further his work on a discovery that plays a critical role in the body's defense against pneumonia.

8 Jan 2010

J&JPRD receives FDA Complete Response Letter for ceftobiprole

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole. The New Drug Application (NDA) was originally submitted to the FDA in May 2007 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections.

30 Dec 2009

Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor

Forest Laboratories announced today its agreement to acquire additional rights to NXL 104, which amends the terms of its prior agreement with Novexel covering the combination of NXL 104 with ceftaroline and adds additional rights to the combination of ceftazidime and NXL 104, through a transaction with AstraZeneca executed immediately following AstraZeneca’s announced acquisition of Novexel, S.A.

24 Dec 2009

Researchers develop new approach for treating and healing skin abscesses

Researchers at the Albert Einstein College of Medicine of Yeshiva University have developed a new approach for treating and healing skin abscesses caused by bacteria resistant to most antibiotics.

23 Dec 2009

New community-associated strain of MRSA more apt to cause serious problems

The often feared and sometimes deadly infections caused by MRSA - methicillin-resistant Staphylococcus aureus - are now moving out of hospitals and emerging as an even more virulent strain in community settings and on athletic teams, and raising new concerns about antibiotic resistance.

23 Dec 2009

Staphylococcus aureus causes far more serious infections than previously realised

Staphylococcus aureus causes far more serious infections than previously realised, with more than 3,000 Swedes affected every year, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

23 Dec 2009

Durata Therapeutics acquires Vicuron Pharmaceuticals

Durata Therapeutics, Inc. announced today that it has acquired Vicuron Pharmaceuticals from Pfizer (PFE). Durata is a newly formed biopharmaceutical company that was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock purchase by New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners.

21 Dec 2009

Malaria nasal vaccine, antimicrobial peptide against MRSA, and safer method to prolong orange juice shelf life

An experiemental nasally administered malaria vaccine prevented parasite transmission from infected mice to mosquitoes and could play an important role in the fight against human malaria. The researchers from Japan report their findings in the December 2009 issue of the journal Infection and Immunity.

19 Dec 2009

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

PolyMedix, Inc., an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has successfully completed the first two segments of a Phase 1B clinical safety study with its novel antibiotic drug candidate PMX-30063.

18 Dec 2009

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that it has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its prophylactic vaccine against Staphylococcus, including Methicillin-Resistant Staphylococcus aureus or MRSA.

17 Dec 2009

Syntiron grants sanofi pasteur exclusive world-wide license to its human vaccine against MRSA

Syntiron today announced that it has granted sanofi pasteur an exclusive world-wide license to its human vaccine against Staphylococcus aureus. The agreement includes an undisclosed initial licensing fee, milestone payments and royalty payments on future sales of the product. Staphylococcus aureus, or MRSA (pronounced Mer-sa) is an important hospital-acquired infection and is a major cause of illness and death resulting in excess of 18,000 US deaths a year and a half million hospitalizations, creating a significant economic burden of approximately $3.4 billion annually to the American health care system.

16 Dec 2009

Pomegranate rind, metal salts and Vitamin C: An effective combination for treating MRSA infection

Pomegranates have already been hailed as a super-food but a team of scientists from Kingston University in South West London has found a new use for the deep red fruit. The team, led by Professor Declan Naughton, has discovered that the rind can be turned into an ointment for treating MRSA and other common hospital infections.

16 Dec 2009

MRSA, the most concerning pathogen to surveyed for skin and skin structure infections

Arlington Medical Resources (AMR) and Decision Resources find that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed European infectious disease specialists with regard to their treatment of skin and skin structure infections.

16 Dec 2009

Post-surgical infections raise healthcare expenditures

Post-surgical infections significantly increase the chance of hospital readmission and death and cost as much as $60,000 per patient, according to Duke University Medical Center researchers who conducted the largest study of its kind to date.

16 Dec 2009

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of serious multi-drug-resistant infections announced today it has entered into a collaborative research agreement with Massachusetts General Hospital (MGH).

16 Dec 2009

Optiquant BKV Quantification Panel for MSSA DNA testing procedures

AcroMetrix, a leading provider of quality control standards for clinical diagnostic laboratories, announced today the launch of the first standardized quality control for MSSA molecular testing.

15 Dec 2009

FDA clears AdvanDx' 90 minutes PNA FISH protocol for S. aureus and CNS tests

AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its S. aureus PNA FISH® and S. aureus/CNS PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.

10 Dec 2009

Staphylococcus aureus News and Research

Further Reading

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

ViroPharma signs agreement with Sanquin Blood Supply Foundation to develop and commercialize Cinryze

Sorrento Therapeutics, Scripps Research Institute announce antibody development collaboration

LSUHSC receives $2.1 million grant for pneumonia research

J&JPRD receives FDA Complete Response Letter for ceftobiprole

Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor

Researchers develop new approach for treating and healing skin abscesses

New community-associated strain of MRSA more apt to cause serious problems

Staphylococcus aureus causes far more serious infections than previously realised

Durata Therapeutics acquires Vicuron Pharmaceuticals

Malaria nasal vaccine, antimicrobial peptide against MRSA, and safer method to prolong orange juice shelf life

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Syntiron grants sanofi pasteur exclusive world-wide license to its human vaccine against MRSA

Pomegranate rind, metal salts and Vitamin C: An effective combination for treating MRSA infection

MRSA, the most concerning pathogen to surveyed for skin and skin structure infections

Post-surgical infections raise healthcare expenditures

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Optiquant BKV Quantification Panel for MSSA DNA testing procedures

FDA clears AdvanDx' 90 minutes PNA FISH protocol for S. aureus and CNS tests

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News